ERR2278867
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.510
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.440
- MYOGENESIS+0.380
- IL6_JAK_STAT3_SIGNALING+0.350
- INFLAMMATORY_RESPONSE+0.340
- UV_RESPONSE_DN+0.340
- HEDGEHOG_SIGNALING+0.330
- IL2_STAT5_SIGNALING+0.280
- KRAS_SIGNALING_UP+0.280
- ALLOGRAFT_REJECTION+0.260
Top 10 suppressed
- PROTEIN_SECRETION-0.440
- OXIDATIVE_PHOSPHORYLATION-0.420
- MYC_TARGETS_V1-0.260
- DNA_REPAIR-0.230
- ADIPOGENESIS-0.180
- UNFOLDED_PROTEIN_RESPONSE-0.180
- GLYCOLYSIS-0.170
- INTERFERON_ALPHA_RESPONSE-0.160
- FATTY_ACID_METABOLISM-0.150
- PI3K_AKT_MTOR_SIGNALING-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | X25d3a106.8a9a.4285.9b02.1ba01b7a9ad2 | — | cohortMD2 | 0.848 |
| 2 | X46c96724.b37b.46c0.9cae.a4a1a5604bf0 | — | cohortMD2 | 0.845 |
| 3 | e074ff82-1def-4bfc-8293-6b69f8984046 | — | — | 0.830 |
| 4 | aad90266-d469-4986-b260-d0df4c2f48e7 | — | — | 0.818 |
| 5 | SRR12202494 | — | — | 0.816 |
| 6 | SRR10900559 | — | — | 0.816 |
| 7 | TCGA-60-2709-01A-21R-1820-07 | — | cohortSQ1 | 0.815 |
| 8 | MNG721 | — | — | 0.812 |
| 9 | X67d3ddec.7e9b.416c.aab4.1960c6294118 | — | cohortA1 | 0.810 |
| 10 | SRR8613814 | — | D | 0.807 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.510 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.440 | Inavolisib | — uncovered |
| MYOGENESIS | 0.380 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.340 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.340 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.330 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.280 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.280 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.260 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.240 | Remibrutinib | — uncovered |
| COAGULATION | 0.240 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.220 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.210 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.190 | Inavolisib | — uncovered |